Episode

Episode 201 - Bennett Smith - SVP Commercial Beren Therapeutics

Podcast
The BioHub - by Avetix
Published
Jul 14, 2026
Duration seconds
1411
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-201---Bennett-Smith---SVP-Commercial-Beren-Therapeutics-e3m2nqt
Audio
https://anchor.fm/s/f0076084/podcast/play/122821917/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-14%2F427939312-44100-2-a2707355db7c2.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-201-bennett-smith-svp-commercial-beren-therapeutics
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-201-bennett-smith-svp-commercial-beren-therapeutics.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-201-bennett-smith-svp-commercial-beren-therapeutics/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-201-bennett-smith-svp-commercial-beren-therapeutics.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of The BioHub Podcast , Max sits down with Bennett Smith, Senior Vice President of Commercial at Beren Therapeutics. Bennett has spent more than two decades building commercial organisations and bringing innovative medicines to patients, holding leadership roles at Novo Nordisk, Regeneron, Akebia, and Orchard Therapeutics, where he helped launch one of the world's most expensive gene therapies. Today, he's leading commercial strategy at Beren Therapeutics, a clinical-stage biotech taking a different approach to developing treatments for rare diseases. In this conversation, we discuss Bennett's journey through biotech, why commercial thinking should begin long before launch, the story behind Beren's emergence from stealth, and what it takes to build a successful commercial organisation from the ground up. We also explore the future of rare disease innovation and why aligning science and commercial strategy from day one can make all the difference.